Navigation Links
Novel Cancer Immunotherapy set to enter Clinical Trials
Date:4/16/2013

LAWRENCEBURG, Ind., April 16, 2013 /PRNewswire/ -- PDS Biotechnology Corporation today presented a summary of the company's preclinical data on its lead cancer immunotherapy PDS0101 at the World Vaccine Congress in Washington DC.  The product is based on the company's ground-breaking and proprietary Versamune™ nanotechnology vaccine platform.  PDS Biotechnology also announced that the company's Investigational New Drug (IND) application had been granted by the FDA allowing PDS0101 to be evaluated in human patients.

PDS0101 is a first-in-class immunotherapy being developed to treat cancers and diseases caused by infection with the human papillomavirus such as cervical cancer, head and neck cancer and cervical intraepithelial neoplasia.  Dr. Frank Bedu-Addo , President and CEO presented the highly promising preclinical efficacy and safety data demonstrating eradication of the tumors without any of the safety drawbacks typical of the current immunotherapy technologies.  PDS0101 is designed to prime the immune system to recruit cells of the body's own immune system to specifically recognize, target and kill the cancer cells.  PDS0101 is also designed to reduce the population of certain immune suppressive cells which prevent our immune systems from detecting and attacking the cancer cells.  "Should the preclinical results be replicated in the clinical setting, this will be a giant leap forward in the development of safe and effective cancer therapies," said Frank Bedu-Addo .

Versamune™ is a nanotechnology-based immune modulating technology which acts by a novel mechanism to prime and activate the immune system to recognize specific diseased cells and disease causing agents.   The technology is unique in its multiple-mode-of-action enabling simple and effective disease-targeting vaccines and immunotherapies to be developed.

About PDS Biotechnology Corporation

PDS Biotechnology is a privately held biotechnology company developing vaccines and immunotherapies based on the company's proprietary Versamune platform.  In addition to PDS0101, the company is also currently developing a potentially game-changing influenza vaccine which in preclinical studies has demonstrated significantly improved speed in which protection against the disease is developed.  In preclinical studies, the strength of the protective immune response was also significantly increased even at lower vaccine doses when compared to the current US licensed flu vaccine.  In June of 2012 PDS granted an exclusive license to Merck KGaA, Darmstadt, Germany for use of Versamune in 2 specific cancer vaccines.  PDS Biotechnology Corporation is headquartered in Lawrenceburg, IN.  Additional information about the company and technology may be found online at http://www.pdsbiotech.com.


'/>"/>
SOURCE PDS Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
2. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
3. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
4. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
5. X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
6. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
7. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
8. A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
9. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
10. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
11. West Announces the Commercial Introduction of a Novel Intradermal Adapter for Disposable Syringes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... its senior management team will host a conference call and webcast ... The dial-in number to access the call is U.S./ ... passcode is 45397076. Please dial in 10 minutes prior to the ... replay of the call will be available from August 8, 2017 ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
(Date:7/11/2017)... N.J. , July 11, 2017  Bayer has awarded ... eight countries as part of its prestigious Bayer Hemophilia Awards ... Hospital of Philadelphia and Uniformed Services ... are among the winners. Grant recipients were announced last ... and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Cosmetic Town, an online plastic ... cosmetic surgeries they perform on a daily basis. , The new video series ... they specialize in at their practices. , When asked about the new video ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... California effectively destroyed the construction site and threatened numerous homes and businesses nearby, ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Every year, ... invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme ... with a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership ...
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Anyone who uses ... a watermelon, nor would a pharmacist using that same scale to dispense medication. The ... health. , These illustrations show why it is important to have the right ...
Breaking Medicine News(10 mins):